The Role of Sex Steroids and Their Metabolites
Changes in serotonin and γ-aminobutyric acid (GABA) levels with estrogen and progesterone metabolites have interaction with the GABA-A receptor complex in neurobiology of PMDD. [24] [25] [26] [27] [28] [29] [30] Studies report that administration of progesterone/ allopregnenolone during the follicular phase enhances amygdala reactivity. 31, 32 Other hormones such as thyroid hormone, melatonin, cortisol and relaxin [33] [34] [35] [36] [37] [38] [39] also have been implicated in the pathophysiology of PMDD.
Calcium, magnesium, insulin-like growth factor 1 and vitamin D [40] [41] [42] [43] [44] have been hypothesized to be responsible for causing various somatic symptoms of PMDD.
Neurotransmitters Implicated in PMS/PMDD
Experiments on animals demonstrate that serotonin depletion causes enhanced aggression and sexual activity. [45] [46] [47] GABA causes tolerance induction and withdrawal effects in such women. 30 Low levels of glutamate/creatine plus phosphocreatine in luteal phase in the medial prefrontal cortex have also been studied. 32 Decreased levels of endogenous opioids are responsible for increased pain sensitivity. 48, 49 In animal studies, an increased startle response is found due to progesterone withdrawal [50] [51] [52] and up regulation of the alpha-4 unit of the GABA-A receptor complex. 51 
Somatic Symptom Pathophysiology
Prolactin-lowering agents, such as the dopamine D2 receptor agonist bromocriptine, 53 ,54 chasteberry 55 administration of danazol in luteal phase, and estrogen receptor antagonists 56, 57 all are effective in mastalgia.
Aldosterone, a progesterone metabolite 58 and deoxycorticosterone, an aldosterone agonist 24, 58 have a role in treatment of severe abdominal bloating.
Other common somatic complaints such as premenstrual headache, migraine, and epilepsy are comorbid with PMDD and endometriosis. 59 
Classification of PMS

Clinical Features
Symptoms in PMDD include anxiety, depression, irritability, anger, bloating, muscle pain, poor concentration, etc., causing severe distress that is persistent in several cycles, characteristically appearing one week before periods and disappearing within first two days of bleeding. 63 Women with PMDD usually have comorbid physical and psychiatric disorders, and one must always keep these comorbidities as dual diagnosis whenever in doubt.
64-72
Management
Thorough investigations for comorbidities must always be done. Among psychological tools, the premenstrual symptoms screening tool was developed at McMaster University in 2003 and a new Japanese scale was made in 2009. 73, 74 There is a scale currently validated for the Indian population as well.
In psychopharmacological treatment, the British Journal of Obstetricians and Gynecologists protocol emphasizes the use of fluoxetine and sertraline in the treatment of PMDD.
60,75
The hormonal therapies recommended by the British Journal of Obstetricians and Gynecologists include leuprolide depot, leuprolide depot with ovarian hormone supplements, goserelin with estrogen supplementation, danazol, oral contraceptive pills, progesterone-only drugs, estradiol patches, spironolactone, bromocriptine, Ibuprofen, etc. 14, 60 In non-pharmacological treatment, lifestyle changes including regular, frequent, small balanced meals rich in complex carbohydrates and low in salt, fat, and caffeine, regular exercise, smoking cessation, alcohol restriction, regular sleep, and maintaining PMDD charts have been found to be helpful. Nutritional supplements including vitamin B6, up to 100 mg per day, vitamin E, up to 600 IU per day, calcium carbonate, 1200 to 1600 mg per day, magnesium, up to 500 mg per day, tryptophan, up to 6 g per day have been suggested.
Others therapies with some benefit include stress reduction and management, anger management, self-help support group, individual and couples therapy, cognitive behavioral therapy, music therapy, light therapy with 10,000 lux cool white fluorescent light, etc.
14,20,60
Conclusion
PMDD is prevalent mental health condition affecting mental and physical well-being of women and yet is underdiagnosed. Careful history and examination regarding PMDD should be a norm in every woman patient presenting to a psychiatrist. Management consists of pharmacological and non-pharmacological intervention with variable prognosis.
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